Q-omics provides the consensus-scored MTND5P25 profile across patient tissues and cancer cell-line models. MTND5P25 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTND5P25 is differentially expressed in 4, with the highest sampling consensus in CHOL. Additionally, MTND5P25 RNA expression shows 14,709 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, CHOL, and THYM as cancer lineages where MTND5P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND5P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND5P25 survival associations across molecular data types. MTND5P25 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND5P25 RNA expression–survival associations across cancer types. High MTND5P25 expression shows unfavorable associations in KIRC, UCS and DLBC, but favorable associations in LUAD, BRCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for MTND5P25 RNA expression.
This table summarizes MTND5P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for MTND5P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND5P25 shows lower tumor expression in PAAD and higher tumor expression in CHOL, STAD and COAD. The CHOL box plot shows higher MTND5P25 RNA expression in tumor versus normal tissue (log2 FC = +0.445, t-test p < 0.001).
This table shows molecular features associated with MTND5P25 in patient tissues and cancer cell lines. In patient samples, MTND5P25 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
